Robin Carrillo is the founder of Myricx Bio. Myricx Bio has raised $114M in total funding. Latest round: Series A. Based in London, UK.
Dr. Robin Carr is the CEO of Myricx Bio, a London-based cancer therapy spinout from the Francis Crick Institute and Imperial College London. He led the company to secure a £90 million ($114 million) Series A round in July 2024. In July 2026, Myricx Bio announced an agreement to be acquired by Novartis.
Full founder directory · Investor directory · Company funding database · Fundraising library